iMAGINE
Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
NCT04488159 Collaboration with J Galon.
Status: Ethic Approved. Recruiting Financial Support
Autors: Längle, Bergmann
CHINOREC
Neoadjuvant CHemoradiotherapy with sequential Ipilimumab and NivOlumab in RECtal cancer: a prospective randomized, open-label, multicenter, phase II clinical trial
EudraCT No 2019-003865-17, NCT 04124601
Financial Support: Bristol Myers Squibb
Status: Recruiting
Authors: Längle, Bergmann
Comparison of PET radio-imaging patterns with immunohictochmistry protein expression pattern in colorectal cancer liver metastases using CXCR4 as target structure.
Financial Support: LBI-Applied diagnostic
Status: recruiting
PI Bergmann
Crohn’s disease: Evalution of Intestinal Fibrosis by FAPI-PET-MR-Enterography: a prospective non-randomized open-label single-center pilot study.
Support: MUV
Status: recruting
PI Scharitzer, CoAutor: Bergmann
A multicenter, randomized, controlled, open label trial on the efficacy and safety of Asunercept for patients with severe COVID-19 disease
NCT04535674
Support: Apogenix, Heidelberg
Status: recruiting
CoAutor: Bergmann
PETNEC
Programmed death-ligand 1 positron Emission Tomography imaging during Neoadjuvant (chemo)radiothErapy in esophageal and rectal Cancer: a prospective non-randomized open-label single-center pilot study
Support: MUV
Status: Ethical approval pos. Seeking compound.
Authors: Längle, Bergmann
Pretherapeutic evaluation of Colorectal Liver Metastasis by FAPI-PET-MRI: A prospective non-randomized open-label single-centre pilot study
Support: LBI and MUV
Status: Seeking Ethical Approval
Authors: Jedamzik, Bergmann